Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by First Horizon Advisors Inc.

First Horizon Advisors Inc. grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,314 shares of the biopharmaceutical company's stock after purchasing an additional 2,119 shares during the quarter. First Horizon Advisors Inc.'s holdings in Regeneron Pharmaceuticals were worth $9,713,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of REGN. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $25,000. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the period. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $28,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 31 shares during the period. Finally, Avalon Trust Co acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth $36,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on REGN. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research note on Monday, June 2nd. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Finally, Robert W. Baird lowered their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $822.58.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $2.74 during mid-day trading on Thursday, reaching $545.00. 456,413 shares of the company traded hands, compared to its average volume of 905,431. The company's 50 day moving average price is $551.63 and its 200-day moving average price is $628.53. The firm has a market cap of $58.84 billion, a PE ratio of 13.87, a PEG ratio of 2.01 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the prior year, the company posted $9.55 earnings per share. The firm's revenue was down 3.7% compared to the same quarter last year. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.